Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2005

View Archived Issues

Activation of mGlu4 receptors - a pharmacological strategy against medulloblastoma

Hypoglycemic effects of FR-225654 in preclinical models of diabetes

Pimecrolimus reported effective in facial seborrheic dermatitis

Amarillo updates low dose oral interferon progress

A novel bimosiamose formulation reduces plaque thickness in psoriasis

NeoPharm establishes bioequivalence for LEP-ETU

LigoCyte receives NIH grant for intranasal anthrax vaccine

Positive results of phase III trial of oxymorphone ER

Genaissance enters into HAP technology license agreement with Sankyo

Phase II program cleared for cholesterol-lowering drug FM-VP4

Acadia receives milestone under Allergan collaboration

Allergan and GSK enter product agreements

Japanese National Institute of Infectious Diseases to study Ampligen

AVR-118 begins phase I study in type 2 diabetes patients

Barbeau Pharma progresses pipeline

EGF/gastrin combination, E1-INT, reverses hyperglycemia and increases beta-cell mass

CTB-Insulin oral vaccine produced in silkworm larvae protects NOD mice from autoimmune diabetes

Anti-IL-13 antibody (CAT-354) effective against allergic airway and esophageal inflammation in mice

Data on novel SERM LY-2066948.HCl

Stockholders of Salix and InKine approve merger

Five reports of Guillain-Barre syndrome following administration of Menactra

Oracea NDA submission accepted for review

Discontinuation of phase III Canvaxin study in stage III melanoma

European approval for Vasovist for magnetic resonance angiography

Update on the antiepileptic effects of adjunctive rufinamide

Antipsychotics demonstrate similar efficacy in schizophrenia patients

Intralesional bleomycin plus electroporation under evaluation for metastatic melanoma

Recent patents disclose novel analgesic agents

New antiinfective agents described in recent patents

New anticoagulants prepared and tested by Aventis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...